Cantonal Hospital of St. Gallen - Recruiting 40 years or older. - Prostatic Artery Embolization vs. Conventional Transurethral Prostatectomy in the Treatment of Benign Prostatic Hyperplasia: A Prospective Randomized Trial.
Merit Medical Systems, Inc. - Recruiting 50 years to 79 years. - Prospective, Randomized, Controlled Investigation of Prostate Artery Embolization With Embosphere Microspheres Compared to Transurethral Resection of the Prostate for the Treatment of Symptomatic Benign Prostatic Hyperplasia.
Eli Lilly and Company - Recruiting 45 years or older. - A Phase 3, Randomized, Double-Blind, Placebo Controlled, Parallel-Design, Multicenter Study to Evaluate the Efficacy and Safety of Tadalafil Once-Daily Dosing in Men With Signs and Symptoms of Benign Prostatic Hyperplasia and Erectile Dysfunction.
Sophiris Bio Corp - Recruiting 50 years or older. - Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of a Single Intraprostatic Treatment of PRX302 for Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (The PLUS 1 Trial).
Samsung Medical Center - Recruiting 50 years to 80 years. - The Comparison of Efficacy Between Holmium Laser Enucleation of the Prostate (HoLEP) and Transurethral Resection of the Prostate (TURP) on the Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostate Hyperplasia (BPH).
Transurethral resection of the prostate; Holmium Laser Enucleation of the Prostate
JW Pharmaceutical - Recruiting 50 years or older. - Observational Study to Evaluate Effect of Thrupasr Capsule on Cardiovascular System in Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia.
University Hospital, Bordeaux - Recruiting 50 years to 85 years. - Study of the Effectiveness and the Tolerance of Intraprostatic A-botulinic Toxin Injection, in the Treatment of Symptomatic Benign Prostate Hypertrophy..
BONT-A intra-prostatic injection; Optimized medical BPH treatment
Ausio Pharmaceuticals, LLC - Recruiting 50 years or older. - Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia.
The University of Texas Health Science Center, Houston - Recruiting 50 years or older. - H-25362: Effect of Botulinum Neurotoxin Type A Prostate Injections on Neurogenesis and Gene Profile Expression in Men With Localized Prostate Cancer and Lower Urinary Tract Symptoms/BPH (Protocol # 05-09-30-03).